ClinicalTrials.gg
RecruitingNCT07149740Updated Feb 13, 2026

Data Gathering for A10900

An observational study in Retinal Disease, Healthy and Glaucoma, sponsored by Optos, PLC. Recruiting at 4 sites in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Optos, PLC · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
180
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Retinal Diseases with a site in United States — 25 open to participants now, 41 under way, 5 of them phase 3. Retinal Diseases · United States.

Planned enrollment
22nd of 51
180 · median 120
Started
2025
with 6 others
Observational
51 of 162
12 open now
Primary completion
2026-05
later than 2 of 37 live
Registered
157th of 162
by date
Lead sponsor
7 of 162
Optos, PLC

Among the 162 studies in Retinal Diseases with a site in United States, this one is the 22nd largest by planned enrollment of the 51 observational ones that give a count, is one of 7 that started in 2025, is one of 51 observational ones, reaches primary completion later than 2 of the 37 other live ones, and was the 157th registered.

Retinal Diseases

333 studies on the registry are indexed under Retinal Diseases; 59 are open to participants now.

Browse Retinal Diseases studies →

Open to participants now

25 of the 162 studies in Retinal Diseases with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Retinal Diseases studies recruiting now, 30 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 16 take children under 18; 19 take healthy volunteers.

This study: 22 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Retinal Diseases with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to gather Optical Coherence Tomography (OCT) data on normal and diseased eyes

03

Conditions studied

  • Retinal Disease
  • Healthy
  • Glaucoma
  • Corneal Diseases
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants with healthy, glaucoma, retinal disease and corneal disease located in different geographic locations in the US

Eligibility criteria

Inclusion/Exclusion Criteria Inclusion Criteria for Retinal Disease Group

  1. Participants 22 years of age or older on the date of
  2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
  3. BCVA 20/400 or better in the study eye
  4. Participants presenting at the site with retinal disease
  5. Diagnosis of some type of retinal pathology by investigator, may include, but not limited to: Macular Degeneration (including participants with drusen and geographic atrophy and choroidal neovascularization), Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Central Serous Retinopathy and others

Exclusion Criteria for Retinal Disease Group

  1. Participants unable to tolerate ophthalmic imaging
  2. Participants not able to obtain acceptable OCT images due to ocular media opacity or other reasons
  3. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
  4. Presence of glaucoma or any ocular pathology other than a retinal pathology in the study eye as determined by self-report and/or investigator assessment at the study visit;

Inclusion Criteria for Glaucoma Group

  1. Participants 22 years of age or older on the date of informed consent
  2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
  3. BCVA 20/40 or better in the study eye
  4. History of Visual field defects within the previous year from the study visit or measured the day of the study visit consistent with glaucomatous optic nerve damage with at least one of the following two findings:

    1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;
    2. Glaucoma hemi-field test "outside normal limits."
  5. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities:

    1. Diffuse thinning, focal narrowing, or notching of the neuroretinal rim, especially at the inferior or superior poles with or without disc hemorrhage;
    2. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue

Exclusion Criteria for Glaucoma Group

  1. Participants unable to tolerate ophthalmic imaging
  2. Participants not able to obtain acceptable OCT images due to ocular media opacity or other reasons
  3. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
  4. No reliable visual field test result within the previous year from the study visit, defined as fixation losses > 33% or false positives > 33%, or false negatives > 33% in the study eye
  5. Presence of any ocular pathology except glaucoma in the study eye Inclusion Criteria for Corneal Group

1. Participants 22 years of age or older on the date of informed consent 2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. Participants presenting at the site with corneal disease, for example but not limited to, corneal disorders due to contact lens wear, post-refractive surgery, dry eye, keratoconus 4. Participant is able to comply with the study procedures.

Exclusion Criteria for Corneal Group

  1. Participants unable to tolerate ophthalmic imaging
  2. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
  3. Participant with ocular media not sufficiently clear to obtain acceptable OCT images.

Inclusion Criteria for Normal Group

  1. Participants 22 years of age or older on the date of informed consent
  2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
  3. Participants presenting at the site with normal eyes (Cataracts, LASIK, PRK, and peripheral pathology that does not affect the posterior pole region, for example lattice and peripheral drusen, are allowed).
  4. BCVA 20/40 or better (each eye)
  5. Participant is able to comply with the study procedures

Exclusion Criteria for Normal Group

  1. Participants unable to tolerate ophthalmic imaging
  2. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
  3. Participant with ocular media not sufficiently clear to obtain acceptable OCT images
  4. History of leukemia, dementia or multiple sclerosis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retinal Disease

    Device: OCT

  • Healthy

    Device: OCT

  • Glaucoma

    Device: OCT

  • Corneal Disease

    Device: OCT

Interventions

  • DeviceOCT

    A10900 is an optical coherence tomography device

06

What researchers measure

Primary outcomes

  1. Number of OCT Scans

    Time frame: 1 year

07

Study locations

3 of 4 sites recruiting
  • Ketchum Health
    Anaheim, California 92807, United States
    Recruiting
  • Eye Disease Consultants, LLC
    West Hartford, Connecticut 06107, United States
    Recruiting
  • Eye Care and Laser Surgery of Newton Wellselley
    Wellesley Hills, Massachusetts 02481, United States
    Completed

    Not enrolling at this site.

  • Charles Retina Institute
    Germantown, Tennessee 38138, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — This is included in the participant's informed consent. Images, demographics, ophthalmic assessments and examinations, visual fields, and ophthalmic and medical history.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for May 2026, 10 months after the start.

Of 54 observational studies under Retinal Diseases, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 17. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Sep 2, 2025
StartActual
Jun 26, 2025
Primary completionEst.
May 1, 2026
CompletionEst.
May 1, 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07149740
Lead sponsor
Optos, PLC
Responsible party
Sponsor
First posted
Sep 2, 2025
Start date
Jun 26, 2025
Primary completion
May 1, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Feb 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion